Discussion on Management of Expert Conflicts of
Interest in Drug Evaluation Process

亚洲社会药学

Discussion on Management of Expert Conflicts of Interest in Drug Evaluation Process

Chen Taohui 1, Zhang Xianglin 2*

1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.Beijing Yeedozencom Healthcare Science &Technology Co.,Ltd., Beijing 100027, China

出版日期:2016-09-20 发布日期:2016-11-21

Discussion on Management of Expert Conflicts of Interest in Drug Evaluation Process

Chen Taohui 1, Zhang Xianglin 2*

1.School of Business Administration, Shenyang Pharmaceutical University, Shenyang 110016, China; 2.Beijing Yeedozencom Healthcare Science &Technology Co.,Ltd., Beijing 100027, China

Online:2016-09-20 Published:2016-11-21
Contact: Zhang Xianglin, guest professor, postgraduate tutor. Major research area: administration of drugs registration. Tel: 010-63365912, E-mail: zhang.xianglin@yahoo.com.cn.

摘要/Abstract

摘要： Objective To explore the concept of expert conflicts of interest in drug evaluation process and the necessity to manage conflicts of interest, and to propose suggestions for regulating expert conflicts of interest in China by learning from experience of drug regulatory authorities in foreign countries. Methods Comparative method was used to study the management of expert conflicts of interest in drug evaluation process in Europe, the United States and China. Results and Conclusion FDA and EU attach great importance to the role of experts in drug evaluation process, and they also cope with the problems of expert conflicts of interest successfully. In contrast, there are some problems in drug evaluation process in China. Therefore, it is necessary to strengthen the transparency of evaluation process to avoid expert conflicts of interest and ensure the impartiality and scientific nature of their opinions.

关键词: American, EU, drug evaluation, expert, conflict of interest

Abstract: Objective To explore the concept of expert conflicts of interest in drug evaluation process and the necessity to manage conflicts of interest, and to propose suggestions for regulating expert conflicts of interest in China by learning from experience of drug regulatory authorities in foreign countries. Methods Comparative method was used to study the management of expert conflicts of interest in drug evaluation process in Europe, the United States and China. Results and Conclusion FDA and EU attach great importance to the role of experts in drug evaluation process, and they also cope with the problems of expert conflicts of interest successfully. In contrast, there are some problems in drug evaluation process in China. Therefore, it is necessary to strengthen the transparency of evaluation process to avoid expert conflicts of interest and ensure the impartiality and scientific nature of their opinions.

Key words: American, EU, drug evaluation, expert, conflict of interest

Chen Taohui, Zhang Xianglin. Discussion on Management of Expert Conflicts of Interest in Drug Evaluation Process[J]. 亚洲社会药学.

Chen Taohui, Zhang Xianglin. Discussion on Management of Expert Conflicts of Interest in Drug Evaluation Process[J]. Asina Journal Of Social Pharmacy.

[1]	Yang Lingling, Xu Fengxiang. EU Real-World Evidence Supports New Drug Research and Development Decisions and Its Implications for China[J]. 亚洲社会药学, 2021, 16(3): 197-202.
[2]	Lan Yipeng, Huang Zhe. Real-World Evidence Supporting New Drug Review and Approval in European Union and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(3): 203-208.
[3]	Yu Zhongyi, Xu Fengxiang. The Enlightenment of EU Real-World Evidence Supporting the Inclusion of Rare Disease Drugs in Medical Insurance Decisions to China[J]. 亚洲社会药学, 2021, 16(3): 209-213.
[4]	Wang JiaoJiao, Huang Zhe. EU Real-World Evidence Supports the Expansion Indications for Drugs and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(3): 214-218.
[5]	Wang Chao, Lian Guiyu. Research on Real-World Evidence and Application in EU and Its Enlightment to China[J]. 亚洲社会药学, 2021, 16(3): 219-224.
[6]	Li Longxiao, Lian Guiyu. How Real-World Evidence Supports Healthcare Decisions in EU and Its Enlightment to China[J]. 亚洲社会药学, 2021, 16(3): 238-241.
[7]	Fu Min, Huang Zhe, Xu Fengxiang. EU Real-World Evidence Supporting Drug Regulatory Decision and Its Enlightenment to China[J]. 亚洲社会药学, 2021, 16(2): 103-107.
[8]	Yuan Hongmei, Zhang Wenfeng, Ma Junhong, Zeng Yingying, Meng Lingquan. Research on the Identification of Core Technologies of China’s Pharmaceutical Cold Chain Based on Patent Analysis[J]. 亚洲社会药学, 2021, 16(2): 128-138.
[9]	Ma Junhong, Zhang Wenfeng, Liu Yue, Yuan Hongmei, Zhang Dawei. Research on the Status Quo and Countermeasures of Patent Application in Liaoning Biopharmaceutical Industry Based on Patent Map[J]. 亚洲社会药学, 2021, 16(2): 145-153.
[10]	Li Meng, Huang Zhe. Empirical Analysis on Performance Evaluation of A Pharmaceutical Company Based on Economic Value Added[J]. 亚洲社会药学, 2021, 16(2): 154-162.
[11]	Yang Yu, Shi Yu, Hu Rongbo, Tian Lijuan. Research and Enlightenment of EU Drug Risk Management Plan[J]. 亚洲社会药学, 2021, 16(1): 23-30.
[12]	Qiao Jiahui, Wang Su, Chen Yuwen. Research on the Relationship between Export Orientation and R&D Investment of China’s Pharmaceutical Industry in Different Regions[J]. 亚洲社会药学, 2021, 16(1): 48-59.
[13]	Bu Hemeng, Xue Aoming, Zhang Fang. Literature Review on the Development of New Drugs Based on TRIZ[J]. 亚洲社会药学, 2021, 16(1): 60-67.
[14]	Cai Hongning, Sun Lihua. Research on the Construction of Pharmacy Organization and the Development of Pharmaceutical Services in China’s Primary Medical and Health Institutions— Based on the Survey of 5 Provinces [J]. 亚洲社会药学, 2021, 16(1): 93-101.
[15]	Chen Yuan, Chen Yuwen. Analysis on the Development Strategy of China’s Pharmaceutical Enterprises under the Background of Volume Procurement[J]. 亚洲社会药学, 2020, 15(4): 193-197.

亚洲社会药学

Discussion on Management of Expert Conflicts of Interest in Drug Evaluation Process

Discussion on Management of Expert Conflicts of Interest in Drug Evaluation Process

PDF

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价